BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
BioLife Solutions Inc. Chief Marketing Officer Todd Berard reported a routine tax-related share disposition. On the release of restricted stock units, 356 shares of Common Stock were withheld by the company to cover his tax withholding obligations. Following this, he directly holds 163,412 shares, so his overall stake remains largely unchanged and the transaction does not represent an open-market sale.
BIOLIFE SOLUTIONS INC executive Mathew Aby J., EVP & Chief Scientific Officer, reported a small, routine share disposition related to taxes. On June 8, 2026, 627 shares of common stock were withheld at $26.10 per share to satisfy tax withholding obligations that arose when restricted stock units were released. After this tax-withholding event, he directly held 389,540 shares of common stock.
BioLife Solutions Inc. ownership update: Casdin Capital, LLC and related entities report shared beneficial ownership of 4,757,165 shares of Common Stock, representing 9.7% of the class as reported on 06/04/2026. The reported shares are held by advisory clients, including Casdin Partners Master Fund, L.P., and the filing disclaims direct sole voting or dispositive power.
BioLife Solutions, Inc. furnished an investor presentation outlining its strategy and recent financial performance for cell-based therapy tools. The company reported pro forma 2025 revenue of $96.2M, up 29% from 2024, with a 65% gross margin and 26% adjusted EBITDA margin.
Q1 2026 revenue was $27.5M with adjusted EBITDA of $6.2M, a 22% margin. Management highlights leadership in biopreservation media, growing adoption across more than 950 active clinical trials and multiple approved therapies, and targets 17–20% revenue growth and positive GAAP net income for full-year 2026.
BioLife Solutions, Inc. investor Casdin Capital and affiliates report a 9.7% beneficial ownership stake, or 4,757,165 common shares. This percentage is based on 48,857,415 shares outstanding as of April 30, 2026. The stake is held through Casdin Partners Master Fund, L.P., its general partner, and Eli Casdin.
The shares were acquired for investment using the fund’s working capital, without specific borrowing for this position. The group states it currently has no concrete plans for corporate changes but may engage with management, directors, and other shareholders on alternatives to maximize shareholder value and could adjust its holdings over time.
BioLife Solutions Inc. reported insider activity by Casdin-affiliated entities. Casdin Partners Master Fund, L.P. completed open-market sales totaling 1,200,000 shares of common stock over three days. The fund sold 300,000 shares at $22.65 on May 19, 2026, 250,000 shares at $23.70 on May 20, and 650,000 shares at $23.70 on May 21. After these sales, the Master Fund continued to hold 4,757,165 shares indirectly. According to the footnote, these securities are owned directly by the Master Fund and may be deemed indirectly beneficially owned by Casdin Capital, LLC, Casdin Partners GP, LLC, and Eli Casdin.
Casdin Partners Master Fund, L.P. submitted a Form 144 notice regarding proposed sales of Common Stock of BLFS. The filing lists 650,000 shares tied to a broker arrangement and records recent dispositions of 300,000 shares on 05/19/2026 and 250,000 shares on 05/20/2026.
BioLifesolutions, Inc. notice of proposed sale of 250,000 shares of Common Stock under a Form 144 by an affiliate. The filing shows the shares were purchased from the issuer on 08/13/2018 and lists a prior sale of 300,000 shares on 05/19/2026 with gross proceeds of $6,795,000.00. The broker identified is BMO Capital Markets and the securities are listed on NASDAQ.
BioLife Solutions submitted a Form 144 notice indicating proposed sale of 300,000 shares of Common Stock. The filing lists an aggregate value of $6,690,000.00 and references 48,857,415 shares outstanding as of 05/19/2026.
The shares were purchased from the issuer on 08/13/2018 for cash; the filing lists BMO Capital Markets as a broker-dealer. The filing is a notice of a planned sale under resale rules.
T. Rowe Price Investment Management, Inc. reported beneficial ownership of 6,506,346 shares of Biolife Solutions Inc. common stock, representing 13.5% of the class. The filing is a Schedule 13G/A amendment signed on 05/15/2026 and states voting and dispositive power is sole for all reported shares.